纳米载体在非酒精性脂肪肝药物治疗中的研究进展

非酒精性脂肪肝（non-alcohol fatty liver disease，NAFLD）已成为当前全球最常见的肝病之一，临床表现为肝脂肪变性，并逐步恶化为非酒精性脂肪肝炎（nonalcoholic steatohepatitis，NASH）、肝硬化、肝癌等末期肝病。目前治疗NAFLD的药物主要包括保肝药物、胰岛素增敏剂、降脂药、抗氧化剂等，但治疗效果尚未满足要求。纳米载体是纳米医学的重要组成部分，具有增加药物溶解性、控制药物释放、促进口服吸收、提高药物治疗效果和降低药物毒性等优势，在NAFLD药物治疗中具有较大的应用潜力，有待深入研究。

Development of Nanocarriers in Drug Treatment of Non-alcoholic Fatty Liver Disease

Non-alcohol fatty liver disease(NAFLD) has become one of the most common liver diseases in the world. The clinical manifestation is liver steatosis, which gradually deteriorates into end-stage liver disease like nonalcoholic steatohepatitis (NASH), liver cirrhosis and liver cancer. Currently, the drugs used to treat NAFLD mainly include hepatoprotective drugs, insulin sensitizers, lipid-lowering drugs, antioxidants, etc., but the therapeutic effect has not yet met the sanative requirements. Nanocarriers are an important part of nanomedicine. They have the advantages of increasing drug solubility, controlling drug release, promoting oral absorption, improving drug treatment effects, and reducing drug toxicity. They have great potential of application in NAFLD drug therapy and need to be further studied.